Sunshine Pharmaceuticals

Sunshine Biopharma is a clinical-stage pharmaceutical company focused on the development of therapies for oncology and antiviral applications. The company's lead oncology candidate, Adva-27a, is a small molecule topoisomerase II inhibitor specifically designed to target multidrug-resistant cancer cells, with an initial focus on pancreatic cancer. In response to the global pandemic, Sunshine Biopharma expanded its portfolio to include SBFM-PL4, a small molecule inhibitor of the SARS-CoV-2 papain-like protease (PLpro). Additionally, the company is exploring monoclonal antibody therapies (KAb) for various solid tumors. Sunshine Biopharma aims to leverage its proprietary drug discovery platforms to address significant unmet medical needs in life-threatening diseases.